Patient-Focused Drug Development At 10: Where Does It Go From Here?
Executive Summary
FDA may conduct more than the 20 required meetings by the end of fiscal year 2017, but how will the patient-focused drug development program find its place in helping generate new drugs?
You may also be interested in...
Patient Advocates Continue To Push US FDA For Central Office
Will a meeting with the agency's new principal deputy commissioner help assure creation of new access point for patient engagement?
US FDA Planning Another Patient Group To Boost Involvement
Patient Engagement Collaborative expected to invite stakeholders to discuss how patient interaction with FDA can improve.
US FDA Patient Affairs Office Could Accelerate Involvement With 'Central Entry Point'
FDA floats idea of central office to coordinate patient engagement for symbolic as well as practical reasons.